Skip to content
D/MD/MD/M5/5005/5005/500

Drawing based on the label description. No photo yet.

“Dapagliflozin and metformin hydrochloride extended-release tablets are available as follows: 5 mg/500 mg tablets are orange, biconvex, capsule-shaped film-coated tablets debossed with "D/M" on one side and "5/500" on other side, may have matt finish appearance”

D M 5 500 pill

Pill with imprint D M 5 500 is orange, capsule, 20 mm and has been identified as Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg. It is used for type 2 diabetes and heart failure. It is supplied by Ascend Laboratories, LLC.

Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg

Imprint
D M 5 500
Strength
Dapagliflozin 5 mg / Metformin Hydrochloride 500 mg
Used for
Type 2 diabetes and heart failure
Color
Orange
Shape
Capsule / oblong
Size
20 mm
Score
No score line
Form
Tablet, film coated, extended release
Manufacturer
Ascend Laboratories, LLC
Drug class
Diabetes medicine (SGLT2 inhibitor)
NDC
67877-619, 67877-619-30, 67877-619-05

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Dapagliflozin and Metformin pills and guides

What is Dapagliflozin and Metformin used for?

Dapagliflozin and Metformin is used for type 2 diabetes and heart failure.

Medicine type
Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label

Dapagliflozin and metformin hydrochloride extended-release tablets are a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dapagliflozin, when used as a component of dapagliflozin and metformin hydrochloride extended-release tablets, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:

  • Sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
  • CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure.
  • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.

Limitations of Use

  • Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Because of the metformin hydrochloride component, the use of dapagliflozin and metformin hydrochloride extended-release tablets is limited to patients with type 2 diabetes mellitus for all indications.
  • Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Dapagliflozin and metformin hydrochloride extended-release tablets are not expected to be effective in these populations.

Pediatric use information is approved for AstraZeneca AB’s Xigduo ® XR (dapagliflozin and metformin hydrochloride) Extended-Release Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.

From the FDA-approved label on DailyMed (published Sep 24, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows D/M and the other side shows 5/500.
  • It is orange, capsule, 20 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Dapagliflozin, Metformin Hydrochloride

Inactive: Lactose Monohydrate, Microcrystalline Cellulose, Low-Substituted Hydroxypropyl Cellulose (11% Hydroxypropyl, 130000 Mw), Hypromellose 2910 (3 Mpa.s), Silicon Dioxide, Magnesium Stearate, Copovidone, Povidone K90, Carboxymethylcellulose Sodium, Unspecified, Polyvinyl Alcohol, Unspecified, Talc, Titanium Dioxide, Glyceryl Monocaprylocaprate, Sodium Lauryl Sulfate, Fd&c Yellow No. 6

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Dapagliflozin and Metformin pills